鼠类葡萄糖素受体的表达克隆和信号特性
L J Jelinek1, S Lok, G B Rosenberg
1ZymoGenetics Inc., Seattle, WA 98105.
概括
研究人员为葡萄糖受体分离了一个互补的DNA克隆,这对于控制血糖水平和了解糖尿病至关重要. 这种受体与葡萄糖结合,触发了细胞内cAMP和的增加.
科学领域:
- 内分泌学 在内分泌学.
- 分子生物学分子生物学
- 细胞信号传递 细胞信号传递
背景情况:
- 葡萄糖和其受体是血糖恒温的关键调节者.
- 血糖控制的失调是糖尿病的核心.
- 了解葡萄糖受体对于糖尿病研究至关重要.
研究的目的:
- 为了隔离和表征葡萄糖受体的补充DNA (cDNA) 克隆.
- 为了研究由葡萄糖素受体激活的信号通路.
- 为了将葡萄糖受体与相关的G蛋白合受体进行比较.
主要方法:
- 使用表达克隆策略来分离葡萄糖受体cDNA.
- 克隆受体蛋白在细胞系中得到表达.
- 进行了连体结合测定和第二信使测量 (cAMP,).
主要成果:
- 一个用于葡萄糖受体的功能补充DNA克隆被成功分离出来.
- 表达的葡萄糖受体与高亲和力结合葡萄糖.
- 葡萄糖的结合导致了腺3',5'-单酸盐 (cAMP) 和的细胞内度增加.
- 葡萄糖素受体与激素和副甲状腺激素受体具有结构上的相似性.
结论:
- 克隆的葡萄糖受体是一种功能性蛋白质,能够结合葡萄糖.
- 葡萄糖受体可以激活信号通路,从而产生两个不同的第二信使:cAMP和.
- 这些发现为了解葡萄糖信号及其在代谢调节和糖尿病中的作用提供了分子基础.
相关概念视频
Assembly of Signaling Complexes
Multiprotein signaling complexes are formed in a dynamic process involving protein-protein interactions at the cytoplasmic domain of transmembrane receptors or enzymatic and non-enzymatic proteins associated with the receptor. These complexes ensure the activation and propagation of intracellular signals that regulate cell functions.
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
Interactions Between Signaling Pathways
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Amplifying Signals via Enzymatic Cascade
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze the...
GPCRs Regulate Adenylyl Cylase Activity
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...
Two...
Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...


